2 news items
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
CYTK
RPRX
22 May 24
, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
CYTK
RPRX
22 May 24
estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently
- Prev
- 1
- Next